Fadi Saab, MD
Cardiovascular Disease · Grand Rapids, MINPI 1528028412
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (43.8%), speaking fees and other — rather than concentrated in one kind of arrangement. 44 manufacturers reported payments, led by Philips North America LLC at 36.5% of the total. Reporting peaked in 2019 at $103,516 and has fallen 77.3% since, to $23,457 in 2025. Among cardiovascular disease clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 528 payments — averaging $652.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Philips North America LLC$126K
- Cardiovascular Systems Inc.$58K
- Terumo Medical Corporation$45K
- Angiodynamics, Inc.$33K
- Medtronic$31K
- Bard Peripheral Vascular, Inc.$11K
- plus $41K from 38 others
Across 69 payments — averaging $1242.76 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim International GmbH$53K
- Boehringer Ingelheim Pharma GmbH & Co.kg$32K
- Medtronic$1K
What the payments were for
- Consulting fees$150,97544%
- Speaking & faculty fees$139,44440%
- Travel & lodging$8,5422%
- Food & beverage$12,6134%
- Other$33,05410%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- (9520) IGT Devices Undivided$86,700
- Peripheral Orbital Atherectomy System$46,321
- Navicross$40,746
- VenaCure EVLT$34,525
- GlideWire$31,800
- Glidesheath$21,450
- GLIDESHEATH SLENDER$19,260
- IGT D Peripheral$18,130
- Auryon Atherectomy Catheter$17,263
- AngioDynamics$17,263
- Soft-Vu$17,263
- Auryon Laser System 100-120 Vac$15,792
- Diamondback Peripheral$15,085
- TurboHawk$13,650
- IN.PACT Admiral$13,000
- LIFESTENT$9,600
- ULTRASCORE$9,600
- Spectranetics Undiv$5,100
- IVUS Systems$5,009
- CT THROMBECTOMY SYSTEM KIT$4,818
How this compares
$344,629 in reported general payments places this provider in the 95th percentile of 760 cardiovascular disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 152 | $132,946 |
| EliquisApixaban | 36 | $44,331 |
| EntrestoSacubitril/Valsartan | 18 | $17,542 |
| Repatha SyringeEvolocumab | 14 | $14,820 |
| Repatha SureclickEvolocumab | 16 | $11,500 |
| FarxigaDapagliflozin Propanediol | 11 | $10,174 |
| Metoprolol Succinate | 60 | $1,350 |
| Atorvastatin Calcium | 84 | $1,332 |
| ClopidogrelClopidogrel Bisulfate | 89 | $1,327 |
| Ezetimibe | 26 | $673 |
| Rosuvastatin Calcium | 33 | $653 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 33 | $554 |
| Potassium Chloride | 15 | $542 |
| Losartan Potassium | 25 | $336 |
| Amlodipine Besylate | 39 | $285 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $96 | $132,946152 claims |
| PfizerEliquis | $186 | $44,33136 claims |
| NovartisEntresto | $89 | $17,54218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 760 cardiovascular disease providers in Michigan.
Other cardiovascular disease in Grand Rapids
- Jihad MustaphaGrand Rapids$1.6M
- Harvinder SinghGrand Rapids$116K
- Chris JacobGrand Rapids$52K
- Marschall RungeAnn Arbor$1.8M
- Vallerie McLaughlinAnn Arbor$947K
- Pedro Villablanca SpinettoDetroit$620K
- Stanley ChetcutiAnn Arbor$573K
- David HainesRoyal Oak$492K
- Steven AlmanyTroy$471K
- David StroblLansing$445K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.